EGFR and non-small cell lung carcinoma: NAZ is currently being examined in combination with various drugs against several malignancies with a focus on EGFR-mutant NSCLC such as in phase I/II study with the c-MET inhibitor INC280 (capmatinib) (NCT02335944), and in a phase II study with trametinib against NSCLC with T790M-positive resistance to EGFR TKI therapy (NCT03516214) [7].